View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2022

Labcorp and Xcell partner to advance cell and gene therapy development

The projects under the alliance will use Xcellbio’s AVATAR incubator system to develop research-grade CAR-T cell material.

Labcorp has announced collaboration with Xcell Biosciences to progress activities that would aid clients in bringing new cell and gene therapies (CGTs) to market. 

Through the alliance, the companies will partner on various projects aimed at enhancing the safety and efficacy of CGTs.

This supports the commitment of Labcorp to expand its worldwide, complete suite of CGT expertise while aiding the pharmaceutical and biotechnology companies to accelerate the development of treatments. 

CGTs alter the genes of a person for treating diseases by disabling or substituting a disease-causing gene, or through the introduction of a new or modified cell or gene.

These therapies are being analysed to treat various ailments, including Parkinson’s disease, solid tumours, rare diseases, and blood-based malignancies.

The projects that are part of the partnership will leverage the AVATAR incubator system of Xcellbio for developing research-grade CAR-T cell material utilised to destroy cancer cells.

This initiative will aid in showing the importance of knowing the parameters of the tumour microenvironment to create CAR-T cells with enhanced performance.

Furthermore, the technology will be leveraged to adapt cancer cells to more physiologic conditions and extend 3D modelling for in vitro CAR-T testing. 

The latest partnership comes after Labcorp made a strategic investment in Xcellbio in November last year. 

Labcorp cell and gene therapy enterprise head and vice-president Dr Maryland Franklin said: “Labcorp is firmly committed to helping our clients bring new treatment options to patients in need while revolutionising the future of medicine with cell and gene therapies.

“By pairing the scale and breadth of our enterprise-wide CGT solutions with Xcellbio’s powerful technology, we have an opportunity to enhance and accelerate the CGT development experience.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU